InvestorsHub Logo
Followers 53
Posts 4314
Boards Moderated 0
Alias Born 02/28/2010

Re: None

Saturday, 07/26/2014 10:20:59 AM

Saturday, July 26, 2014 10:20:59 AM

Post# of 130502
"LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis."

http://www.fiercemedicaldevices.com/press-releases/amarantus-bioscience-licenses-lympro-alzheimers-disease-diagnostic-blood-te

If these are in-line with the numbers that Gerald will release this week the share price will hit the .40-.50 range. The global media coverage on LymPro will be tremendous.

Stay tuned for news.

"The trend is your friend but it's the science that will make you rich."

Twitter: @AmarantusBio .... 10,000+ followers.


p.s. Buckle up!!!